Академический Документы
Профессиональный Документы
Культура Документы
Abstract The HER2/neu oncogene is notable both for its monoclonal antibody that targets the extracellular section of
role in the pathogenesis of breast cancer and its role as a target of the HER2 receptor and has been proved quite effective in
treatment. Qualitative or quantitative protein evaluation has treating patients as a single means or in combination with
been achieved using immunohistochemistry (IHC) on frozen and traditional chemotherapy, being, however, active only against
archival tissues, a widely adopted technique due to the
HER2-overexpressing tumors [2].
standardization of the internal procedural steps and its easy and
low-cost applicability to any laboratory. The goal of the present The American Society of Clinical Oncology has
study is to introduce an efficient tool for the automated detection emphasized on the need for the assessment of HER2 in all
of HER2 protein overexpression in tissues, providing accurate, breast tumors, either in the early stages of diagnosis or in
instant, yet objective interpretation outcomes through a repetitive intervals during the recurrence period. HER2 status
formalized procedure. The comparison of results with can be evaluated using imaging modalities at the DNA level
classifications by specialists who evaluated the same tissue
(using FISH, PCR, or Southern Blot), at the mRNA level
samples dataset confirms the efficiency and prospect of the
(using Northern Blot or RTPCR) or at the protein level (using
methodology.
IHC or Western Blot) [3]. Yet, a preferred detection approach
Keywordssegmentation; protein overexpression; membrane in clinical practice should fulfill the needs for applicability to
staining; active contours; image clustering; color models; archival pathologic tissue slices, ability to reveal their
immunohistochemistry; morphological details, convenience in being routinely used in
most histology labs, and extraction of interpretable and
reproducible results. Based on these requirements, two of the
I. INTRODUCTION
most reliable and widely applied methods include the
Breast cancer constitutes one of the most frequent types of evaluation of gene amplification in the cell nuclei by
cancer among women, yet it can be efficiently treated and fluorescence in situ hybridization (FISH) and the estimation of
cured when it is diagnosed in early stages. Over the last years, protein overexpression at the tumor cell membrane by
medical advances have led to the identification of numerous immunohistochemistry (IHC) [4]. These approaches have the
tumor biomarkers facilitating the understanding of the advantage of being able to correlate between HER2 expression
molecular basis of tumor progression and treatment response. and morphologic features in tissue sections. FISH allows
Prognostic markers aim to objectively estimate the patients selective staining of various DNA sequences with fluorescent
overall outcome, while predictive markers focus on the markers and accomplishes the detection, analysis, and
objective evaluation of the possible benefits from a specific quantification of specific structural abnormalities within
clinical intervention. HER2/neu oncogene amplification nuclei, while IHC uses specific antibodies to stain proteins in
situ, providing the identification of many cell types.
and/or overexpression has been highly associated with breast
tumor evolution because of its prognostic role, as well as its IHC aims at detecting specific antigens in tissues or cells
ability to predict response to specific antibodies. Therefore, based on an antigen-antibody reaction that can be visualized
the evaluation of HER2 status of the cancer is considered by a marker (fluorescent dye, enzyme, radioactive element or
extremely important [1]. Overexpression of this receptor is colloidal gold) and is widely used due to its low cost and high
observed in tumors with much higher level than in normal applicability. When reporting results, the degree of HER2
tissue and is associated with increased disease recurrence, protein-overexpression is scored according to the intensity of
poorer relapse-free survival and worse prognosis. A healthy membrane staining and the percentage of tumor cells stained.
breast cell has 2 copies of the HER2 gene. Some kinds of The evaluation procedure is usually performed qualitatively by
breast cancer arise when a breast cell has more than 2 copies a pathologist, who carefully observes the IHC samples via
microscopy and manually calculates the presence of cancer
of that gene, which start to over-produce the HER2 protein,
cells in the breast tissue, assigning scores according to
forcing the affected cells to grow and divide too rapidly. Due
appropriate criteria and international standards. Yet, the
to the fact that this receptor plays a key role in connecting the interpretation of such results is subjective and causes certain
biological and clinical behavior of several types of cancers, it inconsistencies upon the diagnosis, as the result is highly
is an ideal therapeutic target. Herceptin (trastuzumab) is a
REFERENCES